Medical - Instruments & Supplies · NYSE
Current Price
$159.36
Intrinsic Value
Use the calculator below to estimate
Run a PE ratio stock valuation on Becton, Dickinson and Company with auto-filled earnings data, adjustable target PE, and instant fair value estimate.
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Earnings Yield
3.87%
ROE (TTM)
6.9%
Based on trailing twelve-month data, BDX has earnings per share of N/A and trades at a PE ratio of N/A. These are key inputs for stock valuation using the PE ratio method.
The trailing twelve-month PE ratio of BDX is available in the calculator. This stock valuation metric shows how much investors pay per dollar of Becton, Dickinson and Company's earnings. Use MiniValuator's PE ratio calculator for detailed analysis.
Whether BDX is overvalued depends on comparing its PE ratio to industry peers, historical averages, and growth expectations. A PE ratio above the sector average may indicate overvaluation, but high-growth companies often justify higher PE ratios. Run a full stock valuation on MiniValuator to analyze.
To value BDX using PE ratio: compare its current PE to the sector average, analyze the PEG ratio for growth-adjusted stock valuation, check historical PE ranges, and estimate fair value by multiplying target PE by EPS. MiniValuator's PE ratio calculator automates this analysis.
The PEG ratio of BDX is available in the calculator. PEG ratio divides the PE ratio by the earnings growth rate — a PEG below 1.0 may suggest the stock is undervalued relative to its growth, making it a useful complementary stock valuation metric.
PE ratio provides quick relative stock valuation — how BDX compares to peers. DCF provides absolute stock valuation — what the stock is worth based on projected cash flows. For comprehensive stock valuation, use both methods together. MiniValuator offers both PE and DCF calculators.
